research Alopecia areata and ritlecitinib: Unravelling response trajectories
Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
Search
for
Sort by
Research
900-930 / 1000+ resultsresearch Mice Engrafted with Human Fetal Thymic Tissue and Hematopoietic Stem Cells Develop Pathology Resembling Chronic Graft-versus-Host Disease
Mice with human fetal thymic tissue and stem cells developed symptoms similar to chronic graft-versus-host disease.
research Inheritance-Specific Dysregulation of Th1- and Th17-Associated Cytokines in Alopecia Areata
Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.
research Complete resolution of alopecia totalis following chemotherapy treatment for B-cell acute lymphoblastic leukemia
Chemotherapy for leukemia led to full hair regrowth in a child with alopecia totalis.
research Changes in Populations of HLA- DR+CD3+ Cells and CD57–CD16+ Cells in Alopecia areata after Corticosteroid Therapy
Corticosteroid therapy reduces specific immune cells and promotes hair growth in alopecia areata patients.
research Perforins Expression by Cutaneous Gamma Delta T Cells
Gamma delta T cells in the skin help with healing and defense but can also cause autoimmune issues, and more research is needed to understand how they are activated.
research Exogenous IL-27 prevents the development of alopecia areata
IL-27 can prevent hair loss in alopecia areata.
research Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.
research Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
Farudodstat may help prevent hair loss in alopecia areata by stopping immune attacks on hair follicles.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Autoimmune skin disease pathogenesis: a chronological immune cascade and multi-hit model
Autoimmune skin diseases result from genetic and environmental factors disrupting immune checkpoints.
research Thymic Stromal Lymphopoietin in Cutaneous Immune-Mediated Diseases
A protein called lfTSLP is important in causing allergic and other skin diseases and could be a target for treatment.
research Recurrence of Pemphigus Vulgaris Associated With Interleukin 2 Therapy
A man's skin condition, pemphigus vulgaris, came back after he was treated with interleukin 2 for cancer.
research Thyroid peroxidase antibodies in patients with telogen effluvium
Some people with chronic hair loss may have thyroid autoimmunity.
research 413 DC-HIL+ myeloid-derived suppressor cells are elevated in the peripheral blood and lesional skin of cutaneous lupus patients
Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
research Comparative investigation of immune-related biomarkers related to alopecia areata subtypes
Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.
research Autoinmune Alopecia/Alopecia Areata
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
research Acquired immunogenicity of DNA after modification with malondialdehyde in patients with alopecia areata
Malondialdehyde-modified DNA may trigger an immune response in alopecia areata patients.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Single‐cell transcriptomics reveals a senescence‐associated IL ‐6/ CCR6 axis driving radiodermatitis
Blocking certain immune signals can reduce skin damage from radiation therapy.
research Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study
Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
research The efficacy of a photolyase-based device on the cancerization field: a clinical and thermographic study
The photolyase-based device significantly changed the size and heat of potential skin cancer areas in patients.
research Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.
research 397 Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials
Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.
research 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
research Alopecia areata difusa en paciente con enfermedad tiroidea autoinmune: presentación atípica y revisión de la literatura
Early recognition and thyroid evaluation are crucial for managing diffuse alopecia areata linked to autoimmune thyroid disease.
research A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
The assay effectively identifies compounds that affect immune cell activation.
research Receptor tyrosine kinase Kit action in skin melanocytes: is it exclusively cell autonomous?
KIT's role in skin cells is not entirely independent, as other cells can influence its function.
research Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.